Kidney Cancer News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

First-in-class HIF2? antagonist safe and effective | Nature Reviews ... - Nature.com



First-in-class HIF2? antagonist safe and effective | Nature Reviews ... 
Nature.com
Poorly regulated angiogenesis is a hallmark of many advanced-stage renal cell carcinomas, and the ability of cancer cells to survive and/or proliferate in hypoxic environments might explain resistance to anti-VEGF targeted therapies. Now, data from a ...

and more » 


Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field - FiercePharma



FiercePharma
 
Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field 
FiercePharma
Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field. by Carly Helfand |. Jan 12, 2018 11:04am. Keytruda and Lenvima posted "impressive" overall response rates last year, according to Leerink Partners analyst Seamus ...

 


Dr. Voss Discusses Treatment in the Neoadjuvant Setting for Kidney ... - OncLive



OncLive
 
Dr. Voss Discusses Treatment in the Neoadjuvant Setting for Kidney ... 
OncLive
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment in the neoadjuvant setting for patients with kidney cancer.

and more » 


Your Good Health: Woman's high water intake likely OK - Times Colonist



Your Good Health: Woman's high water intake likely OK 
Times Colonist
Dear Dr. Roach: In 2010, my husband had an abdominal/pelvic CT scan (for an unrelated reason), and they found a 14-millimetre mass in his lower right kidney. In 2017, a repeat scan showed that the mass was much larger, and he had the kidney removed ...

 


Algorithm, MRI images eliminate need for kidney cancer biopsies ... - Health Data Management



Health Data Management
 
Algorithm, MRI images eliminate need for kidney cancer biopsies ... 
Health Data Management
Researchers at UT Southwestern Harold C. Simmons Comprehensive Cancer Center have developed an algorithm used with current magnetic resonance imaging (MRI) technology that can help physicians determine whether kidney tumors are benign or malignant ...
Global Kidney Cancer Drugs Market Share: Abbott, Pfizer, Novartis ... First Newshawk

all 3 news articles » 


Exelixis' Cabometyx Takes Aim at Sutent in Kidney Cancer - Motley Fool



FiercePharma
 
Exelixis' Cabometyx Takes Aim at Sutent in Kidney Cancer 
Motley Fool
After reporting in 2016 that its second-line kidney cancer drug, Cabometyx, outperformed Pfizer Inc.'s (NYSE:PFE) top-selling Sutent in first-line advanced kidney cancer patients, Exelixis Inc. (NASDAQ:EXEL) asked the FDA to expand Cabometyx's label ...
Exelixis soars on blockbuster first-line nod for kidney cancer drug Cabometyx FiercePharma
Exelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer Nasdaq
Cabometyx Wins Indication for Previously Untreated Advanced Kidney Cancer P&T Community
Monthly Prescribing Reference 
all 25 news articles » 


New class of anti-cancer drug effective against kidney cancer ... - Science Daily



New class of anti-cancer drug effective against kidney cancer ... 
Science Daily
A study reports initial findings with a novel drug belonging to a new class of medicines called HIF-2a inhibitors that show promise in treating metastatic kidney cancer.

and more » 


Why This Biotech Stock Is Diving Despite In-Line Liver Cancer Results - Investor's Business Daily



Investor's Business Daily
 
Why This Biotech Stock Is Diving Despite In-Line Liver Cancer Results 
Investor's Business Daily
... Stivarga's earlier trial. Meanwhile, 16% of patients discontinued Cabometyx treatment due to some adverse effects compared with 25% of Stivarga patients, MacKay said. "We anticipate that this is likely due to patients on Cabometyx being more ...
Exelixis, Ipsen Report Positive Results on Lead Cancer Drug Nasdaq

all 10 news articles » 


Pfizer defends kidney-cancer position with Bavencio 'breakthrough' - FiercePharma



FiercePharma
 
Pfizer defends kidney-cancer position with Bavencio 'breakthrough' 
FiercePharma
Pfizer has long expected immuno-oncology rivals to push aside its kidney cancer blockbuster, Sutent. But now, it's getting in on the action with its own I-O product. The FDA has bestowed its breakthrough designation on a combination of Bavencio?the PD ...

 


Dr. Voss on the Future of Clinical Trials for Kidney Cancer - OncLive - OncLive



OncLive
 
Dr. Voss on the Future of Clinical Trials for Kidney Cancer - OncLive 
OncLive
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the clinical trial space for patients with kidney cancer.

and more »